Eisai Co., Ltd.
Clinical trials sponsored by Eisai Co., Ltd., explained in plain language.
-
New drug E7090 shows promise in early trial for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for side effects. In a second part, the drug was also tested in people whose tumor…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 02:40 UTC
-
New hope for japanese women with Tough-to-Treat breast cancer?
Disease control CompletedThis early-stage study tested a new drug called H3B-6545 in 33 Japanese women with a common type of breast cancer (ER-positive, HER2-negative). The main goal was to check the drug's safety and find the right dose. This is not a cure, but a step toward better control of the diseas…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug shows promise for rare bile duct cancer with gene fusion
Disease control CompletedThis study tested an experimental drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion) and has stopped responding to standard chemotherapy. The main goal was to see if the drug could shrink tumors. The drug targets the ca…
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC